Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 3
---
, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. At 12:01 a.m. Eastern time on January 8, 2025, we effected a reverse stock split (the “Reverse Stock Split”) pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. All information has been retroactively adjusted for the Reverse Stock Split. As of January 8, 2025, there are 4,263,026 shares of Common Stock outstanding on a fully-diluted basis after giving effect to the conversion of all outstanding shares of our Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (each as defined below) and the exercise of all outstanding Warrants (as defined below) and options, of which 3,953,972 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 8,000,000 shares of Common Stock offered under this prospectus, including the 4,000,000 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and Offered Common Warrants, were issued and outstanding as of January 8, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 65% of the total number of our fully-diluted shares of Common Stock outstanding and approximately 67% of the total number of our fully-diluted shares of Common Stock held by non-affiliates. You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. Our Common Stock is listed on Nasdaq under the symbol “CERO.” On January 17, 2025, the last quoted sale price for the shares of our Common Stock as reported on the Nasdaq was $2.34 per share. Our existing public warrants (the “Public Warrants”) are listed on Nasdaq under the symbol “CEROW,” and the last reported sale price of the Public Warrants on Nasdaq on January 17, 2025 was $0.0153 per Public Warrant. The Offered Common Warrants do not have the same terms and conditions as our Public Warrants. The actual number of securities, and the combined offering price per share of Common Stock and the accompanying Offer